Manuel Baca

Tri-Institutional Therapeutics Discovery Institute — United States

Medicine · Health Sciences

35h-index4.8kcitations102works11.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(18), Cytokine Signaling Pathways and Interactions(17), Cell death mechanisms and regulation(14), interferon and immune responses(13), Chemical Synthesis and Analysis(9)

Publications102 total

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative Neoplasms
2026Open Access
A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity
PLoS ONE·2025· 2 citedOpen Access
Abstract B079: Interleukin-33 activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
Cancer Immunology Research·2025
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
Journal of Nuclear Medicine·2025· 4 citedOpen Access
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
Nature·2025· 53 citedOpen Access
Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach
Journal of Biological Chemistry·2023· 6 citedOpen Access
Supplementary Figure 4 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 1 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Data from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Methods from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Methods from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 5 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 2 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 3 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 3 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Data from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 1 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 4 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 5 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
Supplementary Figure 2 from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Nicos A. Nicola(13), Douglas J. Hilton(9), David P. De Souza(9), Jian‐Guo Zhang(7), Tracy A. Willson(7), Donald Metcalf(7), Sandra E. Nicholson(6), Stephen B. H. Kent(6), Warren S. Alexander(6), Luba Grinberg(6), Louis Fabri(5), W. Douglas Fairlie(5), Alison Farley(4), Andrew D. Nash(4), Benjamin T. Kile(3), Jason Corbin(3), Shenggen Yao(3), Raymond S. Norton(3), Robyn Starr(3), Vaheh Oganesyan(3)